Document Detail

Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature.
Jump to Full Text
MedLine Citation:
PMID:  22682357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Peritoneal dialysis-associated peritonitis (PD-peritonitis) due to Mycobacterium spp is uncommon. Non-tuberculous Mycobacterium (NTB) PD-peritonitis can present in a similar fashion to more common causes of bacterial PD-peritonitis. We describe the first reported case of multiresistant Mycobacterium fortuitum PD-peritonitis in an Australian patient.
CASE PRESENTATION: A 38 year-old woman developed mild PD-peritonitis during an overseas holiday. Treatment was complicated by delayed diagnosis, requirement for special investigations, treatment with multiple antibiotics, and conversion to haemodialysis following removal of her Tenckhoff catheter.
CONCLUSION: This case demonstrates the diagnostic yield of pursuing further investigations in cases of initially culture-negative, problematic PD-peritonitis. A systematic review of the literature identified only 17 reports of M. fortuitum PD-peritonitis. Similar to our case, a delay in microbiological diagnosis was frequently noted and the Tenckhoff catheter was commonly removed at the time of diagnosis. The type and duration of antibiotic therapy also varied widely so the optimum treatment appears to be poorly defined.
Authors:
Simon H Jiang; Darren M Roberts; Andrew H Dawson; Meg Jardine
Related Documents :
19855297 - Do optic discs get "thinner" or "narrower?".
21187337 - Self-reported goal pursuit and purpose in life among people with dementia.
22439507 - Intermittent self-catheterisation in ms.
24513237 - Bilateral ureteral obstruction revealing a benign prostatic hypertrophy: a case report ...
12213047 - Multiple congenital genitourinary anomalies in a polled goat.
6501847 - A case of fatal strychnine poisoning.
Publication Detail:
Type:  Case Reports; Journal Article; Review     Date:  2012-06-08
Journal Detail:
Title:  BMC nephrology     Volume:  13     ISSN:  1471-2369     ISO Abbreviation:  BMC Nephrol     Publication Date:  2012  
Date Detail:
Created Date:  2012-09-17     Completed Date:  2013-05-24     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  100967793     Medline TA:  BMC Nephrol     Country:  England    
Other Details:
Languages:  eng     Pagination:  35     Citation Subset:  IM    
Affiliation:
Department of Renal Medicine, Concord Repatriation and General Hospital, Concord, New South Wales, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Humans
Mycobacterium Infections, Nontuberculous / complications,  diagnosis*
Mycobacterium fortuitum* / isolation & purification
Peritoneal Dialysis / adverse effects*,  instrumentation
Peritonitis / diagnosis*,  etiology
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): BMC Nephrol
Journal ID (iso-abbrev): BMC Nephrol
ISSN: 1471-2369
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2012 Jiang et al.; licensee BioMed Central Ltd.
open-access:
Received Day: 9 Month: 12 Year: 2011
Accepted Day: 10 Month: 5 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 8 Month: 6 Year: 2012
Volume: 13First Page: 35 Last Page: 35
ID: 3443030
Publisher Id: 1471-2369-13-35
PubMed Id: 22682357
DOI: 10.1186/1471-2369-13-35

Mycobacterium fortuitum as a cause of peritoneal dialysis-associated peritonitis: case report and review of the literature
Simon H Jiang1 Email: Sim_jiang@hotmail.com
Darren M Roberts12 Email: 1darren1@gmail.com
Andrew H Dawson3 Email: a.dawson@uws.edu.au
Meg Jardine14 Email: mjardine@georgeinstitute.org.au
1Department of Renal Medicine, Concord Repatriation and General Hospital, Concord, New South Wales, Australia
2School of Medicine, University of Queensland, Herston, Queensland, Australia
3School of Medicine, University of Western Sydney, Penrith, New South Wales, Australia
4Renal & Metabolic Division, The George Institute for Global Health, Camperdown, New South Wales, Australia

Background

Peritoneal dialysis-associated peritonitis (PD-peritonitis) due to Mycobacterium spp is uncommon, particularly in patients receiving treatment in developed countries. Non-tuberculous Mycobacterium (NTB) PD-peritonitis can present in a similar fashion to more common causes of bacterial PD-peritonitis. However, treatment is often complicated by apparent culture negative dialysate effluent, prolonged treatment courses requiring multiple antibiotics and Tenckhoff catheter removal requiring a change to haemodialysis. We describe the first case of M. fortuitum PD-peritonitis in an Australian patient, requiring Tenckhoff catheter removal and permanent conversion to haemodialysis. The literature is reviewed regarding the presentation and treatment of this condition.


Case presentation

A 38 year-old woman with end-stage renal disease due to Factor-H deficient haemolytic uraemic syndrome had been treated with peritoneal dialysis for 6 months without complication. The patient practiced continuous ambulatory peritoneal dialysis with four exchanges per day of two litres of 2.5% dextrose, each of 4 hour duration. The patient had no prior comorbidities nor history of significant infections. She embarked on a cruise ship holiday in the Pacific. Three days after arriving in North America, she developed nausea which progressed over one week to include mild abdominal pain and diarrhoea. Although her dialysate effluent was cloudy, the mildness of her symptoms prompted the patient to continue the final two weeks of her holiday without any antibacterial treatment. She had no exit site symptoms at any point and reported adherence to her aseptic technique training. Upon return to Australia she promptly presented to hospital.

On presentation to hospital she was febrile (38°C) and tachycardic (108 beats/minute) with a blood pressure of 112/85 mmHg. On examination she had mild abdominal distension and right iliac fossa tenderness. Bowel sounds were present and the Tenckhoff catheter exit site was unremarkable. The peritoneal fluid was turbid with >100 x106/mL leukocytes, predominantly neutrophils.

The peritoneal dialysate cultures were initially reported as culture negative and the patient was treated empirically with intraperitoneal vancomycin and gentamicin. After an early clinical improvement she developed a recurrence of fever and abdominal pain four days after admission. An abdominal computerised tomography scan demonstrated multiple loculations with thin high attenuation rims (Figure 1.). Concurrently, the initial dialysate effluent samples grew gram-positive bacilli after four days consistent with a rapidly-growing non-tuberculous mycobacterium. Gene sequencing by polymerase chain reaction of the isolate identified it to be M. fortuitum. Subsequent antibiotic susceptibility testing demonstrated sensitivity to amikacin and ciprofloxacin, intermediate resistance to cefoxitin, and resistance to clarithromycin, doxycycline, imipenem and trimethoprim/sulfamethoxazole.

The patient underwent surgical removal of the Tenckhoff catheter, disruption of loculations and lavage of the peritoneal space. Her subsequent antibiotic regimen of oral moxifloxacin, clarithromycin and doxycycline was complicated by the development of intolerable nausea. She was then established on oral moxifloxacin and linezolid for six months with a sustained clinical response. Treatment duration was empirically determined. After completion of her course of antibiotics re-insertion of the Tenckhoff catheter was attempted but abandoned after multiple intraperitoneal adhesions were found.


Literature review

We conducted a systematic review of the literature of M. fortuitum PD-peritonitis. 17 reports were identified occurring in 12 males and 5 females aged between 15 and 83 years (Table 1.). The geographic spread included reports from North America (8 patients), Asia (4 patients), Europe (3 patients) and the Middle East (2 patients) with none from Australia.

The duration of symptoms prior to hospital presentation was incompletely reported and a delay in microbiological diagnosis was commonplace (median 7 days, interquartile range 4-8 days). Intra-abdominal loculations and collections occurred in 2 previous reports. The Tenckhoff catheter was removed in all but two reported cases and mostly at the time of diagnosis. The duration of antibiotic therapy varied widely (between 1 and 12 months), so the optimum treatment appears to be poorly defined. In our patient the 6 month duration was chosen based on typically reported dosing periods. Antibiotic sensitivity by disc diffusion was reported in 10 of the 17 reports. M. fortuitum was almost universally sensitive to amikacin, ciprofloxacin, imipenem and clarithromycin. Resistance to cephalosporins, tetracyclines and other macrolides was variable. Similarly, there was marked variability in the antibiotic regimens utilised and the rationale for these choices were incompletely described. The more common antibiotics utilised included amikacin in 7 reports, ciprofloxacin in 4 reports and doxycycline in 3 reports with combination therapy common. Only one death was reported in a patient with M. fortuitum PD-peritonitis (Table 1).


Conclusion

We describe the first case of M. fortuitum PD-peritonitis and the third case of any NTM PD-peritonitis in an Australian patient [15,16]. The place and mode of infection remain unclear. Our patient had recently returned from a one month overseas holiday traversing the Pacific, the Caribbean and North America. Given the slow growth rate of M. fortuitum her peritoneum may have been inoculated either before leaving Australia, whilst travelling through the Caribbean or North America. The slow growth rate of M. fortuitum presumably accounts for the mild and indolent development of symptoms and may be a clinical characteristic of NTM PD-peritonitis. The subacute course may predispose to the chronic sequelae of infection. Our case brings the number of cases with reported intra-abdominal loculations to three in eighteen. This proportion could well be an underestimate with only a minority of reported patients having imaging or persisting with peritoneal dialysis.

The incidence of PD-peritonitis due to Mycobacterium spp. in Australia has not been described. On the basis of registry data, it is anticipated to be low given the relatively high cure rates of all cases of PD-peritonitis in Australia after a median duration of treatment of 13 days with primarily vancomycin or cephalosporins with/without gentamicin [17]. There is considerable variability in the proportion of cases of PD-peritonitis that are culture-negative in Australian and New Zealand renal units which may reflect differences in disease prevalence and/or diagnostic and management practices [17].

Guidelines of the International Society of Peritoneal Dialysis (ISPD) recommend that a negative dialysate culture at 3 days in the presence of ongoing clinical evidence of peritonitis calls for specialized cultures for atypical causes of peritonitis [18]. If there is a clinical suspicion of infection with Mycobacterium spp., repeated smears and centrifuge of effluent sediment with a combination of solid- and fluid-medium culture are suggested.

The safety and timing for attempted re-insertion of Tenckhoff catheters after treatment, and technique survival, is incompletely reported. The ISPD guidelines recommend consideration of catheter removal following a diagnosis of Mycobacterial peritonitis although data supporting this recommendation are limited.

Non-tuberculous Mycobacteria are a rare but serious cause of PD-peritonitis with high rates of Tenckhoff removal and conversion to haemodialysis. This is the first report of M. fortuitum PD-peritonitis reported in Australia and the diagnosis was prompted by inadequate response to empiric antibiotics and confirmed by special investigations that are uncommonly utilised in most cases of PD-peritonitis.


Consent

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.


Abbreviations

ISPD, International Society of Peritoneal Dialysis; IP, Intraperitoneal; IV, Intravenous; NTB, Non-tuberculous Mycobacterium; PD-peritonitis, Peritoneal dialysis-associated peritonitis; PO, Per oral.


Competing interests

The authors declare that they have no competing interests.


Authors’ contributions

SJ, DR and MJ were involved with the clinical management of the patient. SJ and DR drafted the manuscript. All authors revised and approved the final manuscript.


Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2369/13/35/prepub


References
LaRocco MT,Mortensen JE,Robinson A,Mycobacterium fortuitum peritonitis in a patient undergoing chronic peritoneal dialysisDiagn Microbiol Infect DisYear: 19864216116410.1016/0732-8893(86)90151-33956137
Pulliam JP,Vernon DD,Alexander SR,et al. Nontuberculous mycobacterial peritonitis associated with continuous ambulatory peritoneal dialysisAm J Kidney DisYear: 1983266106146846333
Kolmos HJ,Brahm M,Bruun B,Peritonitis with Mycobacterium fortuitum in a patient on continuous ambulatory peritoneal dialysisScand J Infect DisYear: 199224680180310.3109/003655492090624681287816
Woods GL,Hall GS,Schreiber MJ,Mycobacterium fortuitum peritonitis associated with continuous ambulatory peritoneal dialysisJ Clin MicrobiolYear: 19862347867883700629
Tang S,Tang AW,Lam WO,et al. Successful treatment of Mycobacterium fortuitum peritonitis without Tenckhoff catheter removal in CAPDPerit Dial IntYear: 200323330430512938837
Choi CW,Cha DR,Kwon YJ,et al. Mycobacterium fortuitum peritonitis associated with continuous ambulatory peritoneal dialysisKorean J Intern MedYear: 19938125278268143
White R,Abreo K,Flanagan R,et al. Nontuberculous mycobacterial infections in continuous ambulatory peritoneal dialysis patientsAm J Kidney DisYear: 19932245815878213799
Soriano F,Rodriguez-Tudela JL,Gomez-Garces JL,et al. Two possibly related cases of Mycobacterium fortuitum peritonitis associated with continuous ambulatory peritoneal dialysisEur J Clin Microbiol Infect DisYear: 198981089589710.1007/BF019637782512136
Vera G,Lew SQ,Mycobacterium fortuitum peritonitis in two patients receiving continuous ambulatory peritoneal dialysisAm J NephrolYear: 199919558658910.1159/00001352410575188
Youmbissi JT,Malik QT,Ajit SK,et al. Non tuberculous mycobacterium peritonitis in continuous ambulatory peritoneal dialysisJ NephrolYear: 200114213213511411016
Dunmire RB,Breyer JA,Nontuberculous mycobacterial peritonitis during continuous ambulatory peritoneal dialysis: case report and review of diagnostic and therapeutic strategiesAm J Kidney DisYear: 19911811261302063847
Hod T,Kushnir R,Paitan Y,et al. Mycobacterium fortuitum infection in continuous ambulatory peritoneal dialysisClin NephrolYear: 200870654655319049716
Kawamoto S,Otani K,Kawaguchi Y,et al. Mycobacterium fortuitum peritonitis associated with CAPD: diagnosis by a molecular biology techniquePerit Dial IntYear: 199919659259310641784
Renaud CJ,Subramanian S,Tambyah PA,et al. The clinical course of rapidly growing nontuberculous mycobacterial peritoneal dialysis infections in Asians: a case series and literature reviewNephrologyYear: 201116217417910.1111/j.1440-1797.2010.01370.x21272129
Linton IM,Leahy SI,Thomas GW,Mycobacterium gastri peritonitis in a patient undergoing continuous ambulatory peritoneal dialysisAust N Z J MedYear: 198616222422510.1111/j.1445-5994.1986.tb01155.x3463276
Jiang SH,Senanayake S,Talaulikar GS,Peritoneal dialysis-related peritonitis due to Mycobacterium smegmatisPerit Dial IntYear: 201131221521621427257
Fahim M,Hawley CM,McDonald SP,et al. Culture-negative peritonitis in peritoneal dialysis patients in Australia: predictors, treatment, and outcomes in 435 casesAm J Kidney DisYear: 201055469069710.1053/j.ajkd.2009.11.01520110144
Li PK,Szeto CC,Piraino B,et al. Peritoneal dialysis-related infections recommendations: 2010 updatePerit Dial IntYear: 201030439342310.3747/pdi.2010.0004920628102

Figures

[Figure ID: F1]
Figure 1  

Computerised tomography of the abdomen, demonstrating multiple loculations with thin high attenuation rims.



Tables
[TableWrap ID: T1] Table 1 

Published reports ofM fortuitumPD-peritonitis


Location of the report Patient demographics Time from admission to positive culture Sensitivity Directed Treatment Tenckhoff removed Comment
Houston, USA [1]
15 y/o male
4 days
S – Amikacin, trimethoprim/sulfamethoxazole, cefoxitin
IV Amikacin and IV cefoxitin. (c)
Yes
Abscess drainage required
R- doxycycline
Portland, USA [2]
57 y/o male
7 days
Not reported
PO Erythromycin, IV cephapirin, IV tobramycin.(6 days)
Yes
Catheter leak. No abdominal pain. Patient died at 6 days.
Copenhagen, Denmark [3]
35 y/o male
11 days
S – Amikacin, tobramycin, erythromycin, trimethoprim-sulfamethoxazole
IV Amikacin, IV methicillin (c)
Yes
In renal transplant perioperative period.
Cleveland, USA [4]
32 y/o male
6 days
S – Amikacin, tetracycline
Amikacin, tetracycline (1 month); ciprofloxacin (c, d)
Yes
Reduced aural acuity after amikacin.
R – gentamicin, tobramycin, erythromycin, trimethoprim/sulfamethoxazole
Hong Kong, China [5]
65 y/o male
-
Not reported
PO Levofloxacin, PO clarithromycin (12 months)
No
 
Seoul, Korea [6]
54 y/o female
7 days
R – isoniazid, rifampicin, ethambutol, streptomycin
IV Ceftizotime, IV amikacin (c)
Yes
 
Louisiana, USAb[7]
71 y/o male
7 days
Not reported
IP Amikacin and cefoxitin (3 weeks); PO doxycycline and rifampicin (3 months)
Yes
 
83 y/o female
4 days
Not reported
Ciprofloxacin and clofazimine (c, d)
?
Madrid, Spain [8]
42 y/o male
11 days
Not reported
IV Amikacin and PO doxycycline (20 days)
Yes
 
40 y/o male
8 days
Not reported
IV Amikacin and PO doxycycline (1 month)
Yes
Washington, USA [9]
33 y/o male
7 days
S – amikacin, kanamycin, clarithromycin, cefmetazole, imipenem, ciprofloxacin, ofloxacin, azithromycin
PO Clarithromycin and PO trimethoprim/sulfamethoxazole (6 months)
Yes
 
71 y/o female
4 days
R – tobramycin, erythromycin, doxycycline, minocycline, cefoxitin
IV Amikacin, PO clarithromycin, PO trimethoprim/sulfamethoxazole (3 months)
Yes
S – clarithromycin, cefmetazole, imipenem, sulfisoxazole, ciprofloxacin, ofloxacin
I – amikacin, cefoxitin
Saudi Arabia [10]
45 y/o female
7 days
 
PO Isoniazid, rifampicin, ethambutol. (6 months)
Yes
 
Nashville, USA [11]
16 y/o male
12 days
 
PO Ciprofloxacin, PO trimethoprim/sulfamethoxazole (c)
Yes
Perihepatic collection
Kfar-Saba, Israel [12]
65 y/o male
4 days
 
Minocycline (1 monthd)
Yes
Also bacteraemia
Tokyo, Japan [13]
50 y/o male
3 weeks
Not reported
Amikacin, sulbactam (c,d)
Yes
 
Singapore, Singapore b[14] 78 y/o female 8 days S – tobramycin, linezolid, clarithromycin, amikacin IP amikacin, PO ciprofloxacin (3 months) No Patient died at 2 months from malignancy

aThis publication also reported on a suspected case of PD-peritonitis and two confirmed cases of Tenckhoff catheter exit site infections due to M. fortuitum.

bThis publication also listed a second (male) patient with M. fortuitum PD-peritonitis in a table, but described the patient to be a female with M. abscessus PD-peritonitis in the text. Due to inconsistency in the report, this case was excluded.

cDuration of therapy not known.

dRoute of administration not known.

IP intraperitoneal, PO per oral, IV intravenous.



Article Categories:
  • Case Report

Keywords: Mycobacterium fortuitum, Peritoneal dialysis, Peritonitis, Treatment.

Previous Document:  Quality evaluation of various commercial specifications of Polygoni Multiflori Radix and its dregs b...
Next Document:  Resection of liver metastases in patients with extrahepatic disease.